• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

罗沙司他治疗肾性贫血引起横纹肌溶解症 1 例报告。

A case report of rhabdomyolysis caused by the use of roxadustat in the treatment caused by renal anaemia.

机构信息

Department of Nephrology, Affiliated Zhongshan Hospital of Dalian University, Dalian, China.

出版信息

Int J Clin Pract. 2021 Jun;75(6):e14011. doi: 10.1111/ijcp.14011. Epub 2021 Jan 25.

DOI:10.1111/ijcp.14011
PMID:33411966
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8243928/
Abstract

CASE PRESENTATION

In this case, we share a case of one of our patients developed rhabdomyolysis after he was administered roxadustat to treat anaemia caused by chronic renal failure.

DISCUSSION

More than 1.2 million people died from chronic kidney damage (CKD) globally, in 2017. Anaemia is a common complication of CKD. Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that stimulates erythropoiesis and regulates iron metabolism. Roxadustat is often used to treat anaemia caused by renal failure. Its adverse effects include high blood pressure, myocardial infarction, heart failure, high potassium, and dizziness; however, there are no reports about rhabdomyolysis associated with roxadustat.

CONCLUSION

Physicians should be alert about the occurrence of rhabdomyolysis when roxadustat is used.

摘要

病例介绍

本例中，我们分享了一位患者的病例，他在接受罗沙司他治疗因慢性肾衰竭引起的贫血后出现横纹肌溶解症。

讨论

2017 年，全球有超过 120 万人死于慢性肾脏损害（CKD）。贫血是 CKD 的常见并发症。罗沙司他是一种口服低氧诱导因子脯氨酰羟化酶抑制剂，可刺激红细胞生成和调节铁代谢。罗沙司他常用于治疗肾衰竭引起的贫血。其不良反应包括高血压、心肌梗死、心力衰竭、高钾血症和头晕；然而，目前尚无关于罗沙司他引起横纹肌溶解症的报告。

结论

当使用罗沙司他时，医生应警惕横纹肌溶解症的发生。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/223c/8243928/bd0f3d621f12/IJCP-75-e14011-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/223c/8243928/80e93ce6319a/IJCP-75-e14011-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/223c/8243928/bd0f3d621f12/IJCP-75-e14011-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/223c/8243928/80e93ce6319a/IJCP-75-e14011-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/223c/8243928/bd0f3d621f12/IJCP-75-e14011-g002.jpg

相似文献

1
A case report of rhabdomyolysis caused by the use of roxadustat in the treatment caused by renal anaemia.罗沙司他治疗肾性贫血引起横纹肌溶解症 1 例报告。
Int J Clin Pract. 2021 Jun;75(6):e14011. doi: 10.1111/ijcp.14011. Epub 2021 Jan 25.
2
Nonclinical Characterization of the Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat, a Novel Treatment of Anemia of Chronic Kidney Disease.缺氧诱导因子脯氨酰羟化酶抑制剂罗沙司他的非临床特征：慢性肾脏病贫血的一种新治疗方法。
J Pharmacol Exp Ther. 2020 Aug;374(2):342-353. doi: 10.1124/jpet.120.265181. Epub 2020 Jun 2.
3
Efficacy and safety of roxadustat for anaemia in dialysis-dependent and non-dialysis-dependent chronic kidney disease patients: A systematic review and meta-analysis.罗沙司他治疗透析依赖和非透析依赖慢性肾脏病患者贫血的疗效与安全性：一项系统评价和荟萃分析
Br J Clin Pharmacol. 2022 Mar;88(3):919-932. doi: 10.1111/bcp.15055. Epub 2021 Sep 30.
4
Whether Prolyl Hydroxylase Blocker-Roxadustat-In the Treatment of Anemia in Patients with Chronic Kidney Disease Is the Future?脯氨酰羟化酶抑制剂罗沙司他治疗慢性肾脏病患者贫血：未来的方向？
Int J Environ Res Public Health. 2021 Feb 8;18(4):1612. doi: 10.3390/ijerph18041612.
5
A Phase 3, Multicenter, Randomized, Two-Arm, Open-Label Study of Intermittent Oral Dosing of Roxadustat for the Treatment of Anemia in Japanese Erythropoiesis-Stimulating Agent-Naïve Chronic Kidney Disease Patients Not on Dialysis.一项评估罗沙司他间歇口服给药治疗未接受透析的非透析慢性肾脏病且对红细胞生成刺激剂初治的日本贫血患者的 3 期、多中心、随机、双盲、开放性研究
Nephron. 2020;144(8):372-382. doi: 10.1159/000508100. Epub 2020 Jun 24.
6
The role of roxadustat in chronic kidney disease patients complicated with anemia.罗沙司他在慢性肾脏病伴贫血患者中的作用。
Korean J Intern Med. 2023 Mar;38(2):147-156. doi: 10.3904/kjim.2022.318. Epub 2023 Jan 2.
7
Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients.罗沙司他（FG-4592）治疗非透析依赖性慢性肾脏病（NDD-CKD）患者贫血的随机安慰剂对照剂量范围及药效学研究。
Nephrol Dial Transplant. 2015 Oct;30(10):1665-73. doi: 10.1093/ndt/gfv302. Epub 2015 Aug 3.
8
Compassionate use of roxadustat for treatment of refractory renal anemia in an infant.罗沙司他在一名婴儿难治性肾性贫血治疗中的同情用药
Pediatr Nephrol. 2024 Mar;39(3):911-914. doi: 10.1007/s00467-023-06240-1. Epub 2023 Dec 13.
9
Roxadustat in the treatment of anaemia in chronic kidney disease.罗沙司他用于治疗慢性肾脏病贫血
Expert Opin Investig Drugs. 2018 Jan;27(1):125-133. doi: 10.1080/13543784.2018.1417386. Epub 2017 Dec 25.
10
Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for Treatment of Anemia in Chronic Kidney Disease: A Placebo-Controlled Study of Pharmacokinetic and Pharmacodynamic Profiles in Hemodialysis Patients.口服低氧诱导因子脯氨酰羟化酶抑制剂罗沙司他（FG-4592）治疗慢性肾脏病贫血：在血液透析患者中进行的药代动力学和药效学特征的安慰剂对照研究。
J Clin Pharmacol. 2020 Nov;60(11):1432-1440. doi: 10.1002/jcph.1648. Epub 2020 Jun 30.

引用本文的文献

1
Case report: Roxadustat overdose in an anemia patient of chronic kidney disease: insight beyond insignificant consequence.病例报告：一名慢性肾脏病贫血患者罗沙司他过量：超越轻微后果的见解。
Front Nephrol. 2024 Aug 2;4:1413496. doi: 10.3389/fneph.2024.1413496. eCollection 2024.
2
Roxadustat: Do we know all the answers?罗沙司他：我们是否已经了解所有的答案？
Biomol Biomed. 2023 May 1;23(3):354-363. doi: 10.17305/bb.2022.8437.

本文引用的文献

1
Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.全球、区域和国家慢性肾脏病负担，1990-2017 年：2017 年全球疾病负担研究的系统分析。
Lancet. 2020 Feb 29;395(10225):709-733. doi: 10.1016/S0140-6736(20)30045-3. Epub 2020 Feb 13.
2
Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China.口服低氧诱导因子脯氨酰羟化酶抑制剂FG-4592治疗中国贫血患者的2期研究。
Nephrol Dial Transplant. 2017 Aug 1;32(8):1373-1386. doi: 10.1093/ndt/gfx011.
3
Overview of iron metabolism in health and disease.
健康与疾病状态下铁代谢概述。
Hemodial Int. 2017 Jun;21 Suppl 1(Suppl 1):S6-S20. doi: 10.1111/hdi.12542. Epub 2017 Mar 15.
4
Beyond muscle destruction: a systematic review of rhabdomyolysis for clinical practice.超越肌肉破坏：横纹肌溶解症临床实践的系统评价
Crit Care. 2016 Jun 15;20(1):135. doi: 10.1186/s13054-016-1314-5.
5
An overview on safety issues related to erythropoiesis-stimulating agents for the treatment of anaemia in patients with chronic kidney disease.促红细胞生成素刺激剂治疗慢性肾脏病患者贫血相关安全问题概述
Expert Opin Drug Saf. 2016 Aug;15(8):1021-30. doi: 10.1080/14740338.2016.1182494. Epub 2016 May 13.
6
Recombinant human erythropoietin versus placebo or no treatment for the anaemia of chronic kidney disease in people not requiring dialysis.重组人促红细胞生成素与安慰剂或不治疗对非透析依赖型慢性肾脏病患者贫血的疗效比较
Cochrane Database Syst Rev. 2016 Jan 20;2016(1):CD003266. doi: 10.1002/14651858.CD003266.pub3.
7
Changes in Echocardiographic Parameters in Iron Deficiency Patients with Heart Failure and Chronic Kidney Disease Treated with Intravenous Iron.静脉注射铁剂治疗的缺铁性心力衰竭和慢性肾脏病患者超声心动图参数的变化
Heart Lung Circ. 2015 Jul;24(7):686-95. doi: 10.1016/j.hlc.2014.12.161. Epub 2015 Jan 21.
8
Rhabdomyolysis.横纹肌溶解症。
Chest. 2013 Sep;144(3):1058-1065. doi: 10.1378/chest.12-2016.
9
KDOQI US commentary on the 2012 KDIGO Clinical Practice Guideline for Anemia in CKD.KDOQI 美国关于 2012 年 KDIGO 慢性肾脏病贫血临床实践指南的评论。
Am J Kidney Dis. 2013 Nov;62(5):849-59. doi: 10.1053/j.ajkd.2013.06.008. Epub 2013 Jul 25.
10
Intestinal hypoxia-inducible factor-2alpha (HIF-2alpha) is critical for efficient erythropoiesis.肠缺氧诱导因子-2α（HIF-2α）对于有效的红细胞生成至关重要。
J Biol Chem. 2011 Jun 3;286(22):19533-40. doi: 10.1074/jbc.M111.238667. Epub 2011 Apr 15.